Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

104.8K
Overview
104.8K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

115.5K
Overview
115.5K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

103.6K
Overview
103.6K
The Central Dogma01:25

The Central Dogma

139.8K
Overview
139.8K
The Central Dogma01:20

The Central Dogma

33.8K
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
33.8K
Nervous System01:21

Nervous System

3.5K
The nervous system coordinates body functions through its complex network of nerve cells, enabling sensation and movement. It is divided into two primary parts: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS is composed of the brain and the spinal cord. The brain acts as the body's control center, processing sensory information and coordinating responses. The spinal cord functions as a major signaling pathway for the brain and the rest of the body.
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Cancer research communications·2026
Same author

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.

Inflammatory bowel diseases·2026
Same author

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand.

Current oncology (Toronto, Ont.)·2025
Same journal

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same journal

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.

Therapeutic advances in neurological disorders·2026
Same journal

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same journal

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.

Therapeutic advances in neurological disorders·2026
Same journal

Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.

Therapeutic advances in neurological disorders·2026
Same journal

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026
See all related articles

Related Experiment Video

Updated: Feb 4, 2026

Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.9K

Primary central nervous system lymphoma.

Sarah Löw1, Catherine H Han2, Tracy T Batchelor3

  • 1Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

Therapeutic Advances in Neurological Disorders
|October 12, 2018
PubMed
Summary
This summary is machine-generated.

Primary central nervous system lymphoma (PCNSL) requires prompt diagnosis and treatment. High-dose methotrexate-based chemotherapy is the standard for newly diagnosed PCNSL, offering better outcomes and reduced neurotoxicity.

Keywords:
autologous stem cell transplantationmethotrexate primary central nervous system lymphomarituximabwhole brain radiation therapy

More Related Videos

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 4, 2007

16.8K

Related Experiment Videos

Last Updated: Feb 4, 2026

Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.9K
Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 4, 2007

16.8K

Area of Science:

  • Neuro-oncology
  • Hematology
  • Oncology

Background:

  • Primary central nervous system lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma (NHL) affecting the brain and spinal cord.
  • PCNSL management and prognosis differ significantly from systemic NHL.
  • Early diagnosis and treatment are crucial for improving patient outcomes.

Purpose of the Study:

  • To review the current understanding of PCNSL diagnosis and management.
  • To discuss the efficacy and toxicity of various treatment modalities.
  • To highlight challenges in treating relapsed or refractory PCNSL and emerging therapies.

Main Methods:

  • Literature review of primary central nervous system lymphoma (PCNSL) treatment strategies.
  • Analysis of outcomes associated with whole-brain radiotherapy (WBRT), high-dose methotrexate (HD-MTX)-based chemotherapy, and autologous stem cell transplantation (ASCT).
  • Exploration of novel therapeutic targets and immunotherapies for relapsed/refractory disease.

Main Results:

  • High-dose methotrexate (HD-MTX)-based chemotherapy, with or without ASCT or reduced-dose WBRT, improves durable disease control and reduces neurotoxicity compared to WBRT alone.
  • Despite initial treatment response, many PCNSL patients experience relapsing disease with a poor prognosis.
  • Optimal salvage treatment for relapsed/refractory PCNSL remains undefined, necessitating individualized approaches.

Conclusions:

  • High-dose methotrexate (HD-MTX)-based induction chemotherapy is the current standard for newly diagnosed primary central nervous system lymphoma (PCNSL).
  • Ongoing trials are evaluating rituximab and consolidative therapies like ASCT or reduced-dose WBRT.
  • Novel therapeutics targeting molecular pathways and immunotherapy offer future directions for refractory or relapsed PCNSL.